metricas
covid
Buscar en
Neurology perspectives
Toda la web
Inicio Neurology perspectives Mitochondrial function and epigenetic outlook in Leber's Hereditary Optic Neurop...
Información de la revista
Vol. 1. Núm. 4.
Páginas 220-232 (octubre - diciembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2796
Vol. 1. Núm. 4.
Páginas 220-232 (octubre - diciembre 2021)
Review
Open Access
Mitochondrial function and epigenetic outlook in Leber's Hereditary Optic Neuropathy (LHON)
Función de las mitocondrias y consideraciones epigenéticas en la neuropatía óptica hereditaria de Leber
Visitas
2796
S. Mohana Devia,
Autor para correspondencia
geneticmohana@gmail.com

Corresponding author.
, Aswathy P Naira, I. Mahalaxmib, V. Balachandarc
a SN ONGC Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya, Chennai 600 006, India
b Livestock Farming and Bioresource Technology, Tamil Nadu, India
c Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, India
Contenido relacionado
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (2)
Table 1. List of diseases with mutations in nuclear encoding genes for mitochondrial complex 1 subunits and assembly factors.
Table 2. Mitochondrial genetic variants associated with various diseases.
Mostrar másMostrar menos
Abstract
Introduction

Neurodegenerative diseases are reliant on neurons which demand high energy for its functioning, which depends on systems like mitochondrial oxidative phosphorylation (OXPHOS). This energy generated by mitochondria occurs through different respiratory complexes ranging from complex I to IV. Complexes are also known as NADH, including complex I because it is the first enzyme and largest chain of the given respiratory chain; however, complex 1 is called the ubiquinone oxidoreductase. Majority of neurodegenerative cases demonstrate irresistible evidence of plenty of mitochondrial subtleties that are impaired, as inhibition of complex 1 could lead to excessive reactive oxygen species (ROS) production.

Development

In this review we try to discuss on how epigenetic modifications could cause a drift in smooth functioning of mitochondria and its function leading to neurodegenerative diseases like Leber's hereditary optic neuropathy (LHON). The reference articles were collected from NCBI-Pubmed, Scopus and Web of science. This review tries to deliver a summarizing overview related to Complex 1 mediated mitochondrial dysfunction and studies done so far in this aspect, along with the epigenetic modifications.

Conclusion

In this review we discussed the different roles of mitochondria and its related dysfunction in the pathogenesis of neurodegenerative diseases.

Keywords:
Epigenetics
Leber's hereditary optic neuropathy
Mitochondrial complex 1
Neurodegenerative diseases
Nuclear encoded mitochondrial proteins
Resumen
Introducción

Las neuronas necesitan grandes cantidades de energía para su funcionamiento y dependen de sistemas como la fosforilación oxidativa mitocondrial. Dicha energía se genera en las mitocondrias a través de diferentes complejos respiratorios (complejos I-IV). El complejo I, también conocido como nicotinamida adenina dinucleótido (NADH por sus siglas en inglés) o ubiquinona oxidorreductasa, es la primera enzima y el mayor complejo de la cadena respiratoria. La mayoría de enfermedades neurodegenerativas se asocian de forma inequívoca a una gran variedad de alteraciones mitocondriales, como la inhibición del complejo I, que podría desencadenar una sobreproducción de especies reactivas de oxígeno.

Desarrollo

El objetivo de nuestra revisión es analizar cómo las modificaciones epigenéticas pueden alterar el funcionamiento normal de las mitocondrias, lo que puede a su vez favorecer el desarrollo de enfermedades neurodegenerativas como la neuropatía óptica hereditaria de Leber. Hemos usado las bases de datos PubMed, Scopus y Web of Science para identificar artículos relacionados. Esta revisión presenta un resumen de la evidencia disponible hasta la fecha sobre la disfunción del complejo I mitocondrial y las modificaciones epigenéticas identificadas.

Conclusión

Analizamos el papel de las mitocondrias y las disfunciones mitocondriales en la patogénesis de las enfermedades neurodegenerativas.

Palabras clave:
Epigenética
Neuropatía óptica hereditaria de Leb
Complejo mitocondrial I
Enfermedades neurodegenerativas
Proteínas mitocondriales codificadas en el núcleo
Texto completo
Introduction

Mitochondrial diseases are inherited genetically which occurs when mitochondria is unable to proceed oxidative phosphorylation. This happens due to mutations in mitochondrial genes and nuclear genes which encodes structural mitochondrial proteins. Mitochondrial DNA mutations are transmitted by maternal inheritance and nuclear DNA mutations may follow an autosomal dominant, autosomal recessive or X-linked inheritance pattern. Mitochondrial diseases prevalence is estimated around 1 in 5000 in adults.1 Deficiency of complex 1 due to pathogenic mutations leads to various mitochondrial diseases. Various nuclear gene as well as mitochondrial gene mutations have been identified which has been associated with mitochondrial complex 1 deficiency. Mutations in genes which codes for structural subunit and assembly factors of complex 1 is referred as Primary complex 1 defects.2 Factors such as mitochondrial dysfunction, oxidative stress and apoptosis have an important role in various ocular diseases whereas oxidative stress and mutations in mitochondrial protein encoding genes are associated with several neurodegenerative diseases.3 Epigenetic regulation among nuclear geneswhich encodes for complex 1 subunitswould make evidentchanges in expression of complex 1 subunit. This changes in mitochondrial protein level would lead to defective oxidative phosphorylation and energy depletion in cells.

Focusing on the range of genomic mechanism which not only relies on the sequence of DNA but also other factors is epigenetics. It is important to integrate cues from the environment in order to understand the development of regulated genetic complication and control homeostasis. There are various studies carried out in epigenetics against embryology, cellular differentiation and aging. In the last decade there are many pioneering studies focusing on epigenetics that include acetylation, methylation, ubiquitylation and phosphorylation which are natural occurring processes that take place in every organism, and changes in these can cause unwanted effects on health leading to various diseases/disorders.4 Researches in epigenetic regulation of nuclear encodedmitochondrial genes will lead to better understanding of various mitochondrial diseases and increases the chances to find out better therapeutics in future.

Mitochondria and oxidative phosphorylation

Oxidative phosphorylation consists of five enzyme complexes which are embedded in the inner mitochondrial membrane.5 Mitochondria is the only one organelle in eukaryotic cell which have their own genome separately. The mtDNA is located in the matrix and each mitochondria contain several identical copies of mtDNA.6 Other than the energy production, mitochondria have several unique function in control of cell cycle, regulating cell signaling, maintaining cell death and other cellular metabolism.7 Oxidative phosphorylation is a complex process and OXPHOS system that requires a large group of mitochondrial as well as nuclear encoded proteins to function accurately.8 OXPHOS system includes complex I (CI or NADH:ubiquinone oxidoreductase), complex II (CII or succinate:ubiquinone oxidoreductase), complex III (CIII or ubiquinol:cytochrome-c oxidoreductase), complex IV (CIV or cytochrome-c oxidase) and Complex V (FOF1-ATP-synthase). The flow of electrons from NADH/FADH2 to O2 through this subunits located in the mitochondrial inner membrane leads to the pumping of protons out of the mitochondrial matrix and its generate ATP.9

Role of complex 1 in oxidative phosphorylation

OXPHOS subunit Complex I (NADH:ubiquinone oxidoreductase) is the largest subunit and C1 is boot shaped structure of ~1 MDa and being composed of the hydrophobic membrane arm and the hydrophilic matrix arm perpendicular to each other. The matrix arm consists mostly of the nuclear-encoded subunits, FMN, three iron–sulfur clusters and site for internal ubiquinone. The membrane arm has all mtDNA-encoded subunits, one iron–sulfur cluster and catalytic site for the substrate ubiquinone.10 Central C1 subunits arranged as three functional modules: 1) N module, the electron input module that oxidizes NADH 2) Q module that reduces ubiquinone and 3) P module that translocate proton across the membrane.11 N module comprising NDUFV1, NDUFV2, NDUFS1 subunits, in which electron entering to N module through FMN from NADH. FMN is non-covalently bound to NDUFV1 and it transfers the electron to Fe–S clusters N3, N1b, N4, and N5.12 The Q module is composed of NDUFS2, NDUFS3, NDUFS8, and NDUFS7 subunits and it accepts electrons from the iron–sulfur clusters of the N module and transfers the electrons through iron–sulfur clusters N6a, N6b and N2 to ubiquinone.13 Study has been reported about complex 1 deficiency in drosophila model which is caused by homoplasmic mutation in ND2 gene. This mutant model exhibits phenotypes that resemble symptoms of mitochondrial disease, short lifespan, progressive neurodegeneration, altered mitochondrial membrane potential and low level ATP production.14 P module is membrane embedded and it mediates proton pumping. P module comprising the seven mitochondrial DNA-encoded CI subunits (ND1, ND2, ND3, ND4, ND4L, ND5, ND6), ND1 at the base of the Q-module, followed by ND3, ND6 and ND4L, and the antiporter-like subunits ND2, ND4 and ND5.11,15 Majority of the complex 1 subunit proteins for assembly and accessory factors are encoded by nuclear genes, those proteins are synthesized in cytosol and imported into the mitochondria through translocation machineries.16

There are studies which show that biosynthesis of complex 1 is a complicated process and many assembly factors are involved in each step of the process.17 Many studies have been conducted to understand the different stages of complex 1 assembly process and its integration into the respiratory chain super complexes.18 Recent study proving that modules of complex 1 were found to form five different subassemblies, comprising all 14 central and 18 accessory subunits corresponding to almost 80% of the total mass of fully assembled complex I.18 The N module core subunits NDUFV1, NDUFV2 and NDUFS1 and accessory subunits NDUFV3, NDUFS4, NDUFS6 and NDUFA12 are integrated at last to form complex 1 functional holo-enzyme.19 Accessory subunits form a scaffold around the core subunit to prevent ROS generation and for the protection against oxidative damage by shielding redox groups from reaction with oxygen, in binding of the CI to the membrane, and in the stabilization of the enzyme. Also, more specific functions in the regulation of activity or the assembly of other subunits into the holocomplex have been implied.20 The Complex I assembly factors NDUFAF1, ACAD9, ECSIT, TMEM126B, and TIMMDC1 form the MCIA complex, which was identified in human osteosarcoma 143B cells by complexome profiling.21

Complex 1 mediated ROS production and oxidative stress

Oxidative stress is the imbalance between reactive oxygen species (ROS)/reactive nitrogen species (RNS) generation and the biological antioxidant defense system. The accumulation of ROS in cells and changes in functional level of macromolecules leads to damage of tissue to organ and contributes to pathogenensis of many diseases.22 ROS production can happen in mitochondria in two different ways: (1) In results of complex 1 inhibition, the electrons are backed up within the Fe–S cluster of complex 1. (2) Reverse electron transfer, where electrons are going backward to complex 1 from complex II via ubiquinone which generate superoxide from semi-ubiquinone at the quinine-binding site.23 Mitochondrial inner membrane is the major site of ROS production and mitochondrial DNA (mtDNA) are more prompt for ROS damage. mtDNA damage is more substantial and persist longer than mutations in nuclear DNA.24 mtDNA is more susceptible for oxidative stress than nDNA because of its close proximity to the inner mitochondrial membrane: major production of ROS site as well as mtDNA is not protected with histone or any other associated proteins and intronless regions, all these factors enhance the oxidative modification in the genome. Effect of mitochondrial damage reflects on the mtDNA as well as mtRNA transcrits reduced level and alterations in mitochondrial function.25 ROS also attacks structural and enzymatic proteins through the oxidation of aminoacids, prosthetic group, formation of cross links and proteolysis. Inhibition of key proteins can lead to serious consequences in the metabolic pathways. mtDNA can be displaced to intra- and extracellular compartments in response to various stress conditions. Displacement of mtDNA from mitochondria is still unclear and studies are indicating that through the generation and release of extracellular vesicles mtDNA transfer to extracellular compartment is possible.26,27

Studies have illustrated that several mitochondrial diseases are associated with ROS mediated mtDNA mutation. In MELAS, hydroxyl radical damage to mtDNA and it can accelerate the mitochondrial genotype associated with the disease.28 In MELAS and MERRF patients, intracellular ROS level and oxidative damage to macromolecules were increased in skin fibroblast cells.29 ROS associated telomerase shortening have been observed in patients with MELAS-related mitochondriopathy and patient with LHON.30 In Leber's hereditary optic neuropathy (LHON), all associated point mutations such as ND1, ND4 and ND6 are enhancing ROS production.31 Increased or decreased ROS production leads to oxidative stress condition in cells and it induces mitochondrial DNA mutations, damage the mitochondrial respiratory chain, amend membrane permeability and it has impact on Ca2+ homeostasis and mitochondrial defense systems.32 As a consequence of LHON point mutation, oxidative stress is responsible for cellular damage and activates apoptosis in RGCs.33 Oxidative stress cause DNA damage and level of DNA damage marker (8OH2'dG) has been shown raised in LHON patient leukocyte.34 Human osteosarcoma cybrid cells with LHON mutations were also showed reduced GSH activity.35 In animal model study showed ATP production remains same while oxidative stress remains as high indicating the role of ROS as a source of RGC degeration.36

Diseases associated with mutations in mitochondrial complex 1 dysfunction

Assembly defects in complex 1 lead to improper functioning of electron transport chain and severe disease conditions. Various mutations in mitochondrial and nuclear genes associated with complex 1 cause most of the mitochondrial diseases.37 Almost 25 genes have been identified for complex 1 deficiency in which 6 genes are nuclear encoded accessory protein genes and 19 mitochondrial genes codes for complex 1 subunits. Proper assembly of subunits and accessory proteins are required for the stability and functioning of complex 1.38 Pathogenic mutations have been identified in mitochondrial genes for Leigh syndrome, multisystem disorders such as MELAS (mitochondrial encephalopathy with lactic acidosis and stroke like episodes), or MELAS/LHON overlap syndromes,39 Leber's Hereditary Optic Neuropathy (LHON), and MERRF (myoclonic epilepsy and ragged red fibers), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes.

Syndrome resembling strokes are associated with severe complex I deficiency caused by mitochondrial DNA (mtDNA) mutations.12 Among mitochondrial disorders, MELAS syndrome is considered as one of the most common maternally inherited diseases and the pathogenicity of MELAS is still not well understood.40 Study using MELAS neuronal cybrid cells reported a homoplasmic m.3243A > G mutation which is a metabolic switch towards glycolysis with the production of lactic acid. It shows severe defects in respiratory chain activity and complex I disassembly with an accumulation of assembly intermediates. Studies showed that Ketone Bodies (KB) exposure during 4 weeks associated with glucose deprivation significantly restored complex I stability and activity, increased ATP synthesis and reduced NADH/NAD+ ratio, mtDNA copy number were significantly increased with KB. KB may constitute an alternative and promising therapy for MELAS syndrome, and could be beneficial for other mitochondrial diseases caused by complex I deficiency.41

Mutations in nuclear encoded structural subunit genes and in assembly factor genes are associated with severe clinical presentations like Leigh syndrome, Leigh like syndrome, leukoencephalopathy with macrocephaly, leukoencephalopathy, lethal infantile mitochondrial disease, cardiomyopathy and encephalopathy, unspecified encephalomyopathy, progressive cavitating leukoencephalopathy, hypertrophic cardiomyopathy and encephalomyopathy are associated with mutations in nuclear encoded complex 1subunits.42,43 In 1998, first study about mutation in nDNA encoded complex 1 subunit was reported and the study was on heterozygous mutation in NDUFS8 gene in a patient with Leigh syndrome with complex 1 enzyme deficiency in muscle tissue and cultured skin fibroblast.44 Leigh syndrome is the most common clinical presentation of mitochondrial diseases in children and mutation causing Leigh syndrome have been detected in almost all complex 1 gene including both nuclear and mitochondrial genes.45 The emerging use of whole exome sequencing (WES) has become an essential tool in identification of the heterogeneous molecular background of complex I deficiency and discovery of novel disease genes underlying this condition.46

Oxidative stress and complex 1 associated neurodegenerative diseases

Brain tissue has high energy demand and central nervous system functions strongly depending on efficient mitochondrial function. Mutations in mitochondrial genome, alterations in mitochondrial dynamics, ROS generation, pathologic protein aggregations and environmental factors may alter energy metabolism and it leads to neurodegenerative diseases.73 Oxidative stress mediate mitochondrial alterations which might be a major reason for neurodegeneration.74 Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradually progressive, selective loss of neuronal systems which are physiologically or anatomically related. The most common chronic neurodegenerative diseases associated with aging and aggregation of misfolded proteins are AD, PD, HD and ALS. Many studies have proved that complex 1 activity significantly decrease in cortex, cerebellum and brainstem mitochondria from aged sample group compared to young control group.75,76 Neuronal damage occurs as the effect of imbalance of ATP production, membrane potential and calcium uptake, in neurodegenerative processes, increased ROS leads to all these imbalance conditions. In 1990, first study has been reported about the role of mitochondria in neurodegenerative process associated with Parkinson's disease where complex I deficiency was observed in substantia nigra and platelet mitochondria of patients.77 Mitochondrial complex 1 activity is reduced in the substantia nigra of PD patients and study using complex I inhibitors such as rotenone, MPTP and pesticides cause neurological changes similar to PD.78 Partial inhibition of complex I in nerve terminals is sufficient for mitochondria to generate more ROS. H2O2 plays a major role in inhibiting complex I as well as ketoglutarate dehydrogenase which results in higher ROS production in dopaminergic neurons leading to excessive oxidative stress and ATP deficiency that eventually will result in cell death in the nigro-striatal pathway.79 In a PD related study demonstrated that complex 1 inhibition increased free radicals and reduced proteasomal activity via adenosine triphosphate (ATP) depletion and it increases neuronal vulnerability.80 Combinational effect of decreased complex 1 activity, reduced cellular ATP levels, increased ROS levels lead to reduced ATP dependent axonal transport, reduced proteosomal degradation and cytoplasmic accumulation of the tau protein. Hyperphosphorylated tau may be one of the factor that contribute to the apoptosis process and its sufficient to cause neurodegeneration.81 Accumulation of mutant aggregate-prone proteins induced by proteasomal inhibition in neurodegenerative diseases results in impairment of the mitochondrial respiratory chain complexes activity.82

In AD, membrane-associated oxidative stress, increased free radical production and perturbed Ca2+ homeostasis have been observed and also COX activity is reduced and neurons exhibit mitochondrial damage and apoptosis.83 Changes in oxidative metabolism in AD showed as a result of changes in gene expression of nuclear and mitochondrial genes encoding for complex 1 enzyme. Decreased complex 1 activity as the result of down regulation of mitochondrial genes have been found in AD brain specimens.84,85 Decreased gene expression of ND4 subunit of complex 1 also has been reported in the temporal cortex of AD patients.86 Appearance of h Aβ aggregation and Tau pathologies correlate with mitochondrial dysfunctions in neurons in AD.Elevated Ca2+ and ROS levels during mitochondrial dysfunction both contribute to the accumulation of pTau aggregates. In 2007, Melov et al. showed that mitochondrial SOD2 deficiency can result in pTau aggregation in mice, a symptom that is reversible by the administration of antioxidants.87

Other neurological disorders like bipolar disorder and schizophrenia are also linked to mitochondrial dysfunction and oxidative stress. It still remains unclear whether mitochondrial dysfunction is specifically associated with complex I impairment or associated with increased oxidative damage and, if so, whether this relationship is specific to bipolar disorder.88 Levels of NDUFS7 and complex I activity were decreased significantly in patients with bipolar disorder but were unchanged in those with depression and schizophrenia compared with controls88 (Table 1).

Table 1.

List of diseases with mutations in nuclear encoding genes for mitochondrial complex 1 subunits and assembly factors.

Disease  Complex 1 subunit  Mutation  Study sample  Reference 
Leigh syndromeLeigh syndromeLeigh syndromeNDUFS1  L23Ndel 222D252GM707VR241WR557WOne large-scale deletionL23N  Skin fibroblastBlood sample  4748 
NDUFV1  Y204CC206GE214KIVS 8 + 4A432Pdel nt 989–990  Skin fibroblast  47 
NDUFS2  D446NM292T  Fibroblast cells  4950 
NDUFS3  T145IR199W  Skin fibroblast  51 
NDUFS4  Splicing mutation of intron 1 (IVS1nt −1) cHomozygous 5 bp duplicationC316TG44Ahomozygous c.462delA  Skin fibroblastSkin fibroblastSkin fibroblastSkin fibroblastPatient blood  5253545556 
NDUFS7  V122 M(c.17–1167 C > G) Exon 1  Skin fibroblastPatient blood  5758 
NDUFS8  P79L/R102HP85LR138H  Skin fibroblastSkeletal muscle and lymphoblast DNA  4459 
NDUFA2  skipping of exon 2  Skin fibroblast and muscle tissue  60 
NDUFA10  Q142R  Fibroblast and muscle tissue  61 
NDUFAF2  p.Y38X)c.l03delAp.W74X  Fibroblast cells  62 
FOXRED1  N430SQ232XR352W  Skeletal muscle and liver cells  63 
LeukoencephalopathyNDUFV1  A341V  Skin fibroblast  64 
NDUFS1  Q522K  Fibroblast  65 
Mitochondrial encephalopathyNDUFA1  G32Rc.94G > C  Lymphoblast cellsBlood and fibroblast cells  6667 
NDUFAF2  R45XM1L  Fibroblast cells  62 
NUBPL  G56R  Skeletal muscle and liver cells  68 
ACAD9  R532WR417C  Fibroblast  69 
NDUFV2  (IVS2 + 5_ + 8delGTAA  Skin fibroblast  70 
NDUFV1  R45X  Fibroblast cells  71 
Fatal infantile lactic acidosis  NDUFA11  IVS15g-aLeaky mutation  Fibroblast cells  72 
Leber's Hereditary Optic Neuropathy (LHON) and epigenetic studies in LHON

Ocular diseases also involved in mitochondrial diseases and ocular changes are noticeable feature in various mitochondrial diseases. Eye is high energy demanding organ and mitochondrial DNA damage as the result of oxidative stress studied in pathogenesis of various opathalmologic diseases such as diabetic retinopathy (DR), age-related macular degeneration (AMD) and glaucoma.89 First study in DR demonstrate the overall mtDNA damage in the retina in animal models and shows that this damage continues even after hyperglycemia is reversed, suggesting a strong role for mtDNA damage in the development, and also in the metabolic memory associated with the progression of DR.90 Mitochondrial abnormality in ophthalmic disease associated with complex 1 dysfunction in LHON leads to optic nerve damage specifically involving retinal ganglion cells.

Leber's Hereditory Optic Neuropathy (LHON) is a maternally inherited mitochondrial disorder which leads to bilateral vision loss by degeneration of retinal ganglion cells. Point mutations in the mtDNA which code for NADH dehydrogenase subunit of Complex 1 in the ETC causes the progressive vision loss.91 The three common primary mitochondrial mutations are m.11778G4A in MT-ND4 gene, m.3460G4A in MT-ND1gene and m.14484T4C in MT-ND6 gene. The prevalence for the disease is estimated to 1:3000 and LHON begins generally in the mean age onset between 18 and 35, it happens around 50% in male and 10%–50% in females.92 In the earlier stage of the disease, acute or subacute, painless vision loss in one eye and gradually within few weeks it will affect the second eye also. Majority of patient will remain blind and it affect the overall quality of their life.93 Sometimes LHON misdiagnosed as optic neuritis at early stage due to acuity of onset, age at presentation.94 Recently one study has been reported, a case with painful unilateral optic neuritis pave the way for the onset of LHON. It is not clear whether any mechanism are commonly sharing with these diseases or optic neuritis acted as a activating factor for LHON disease condition.95 Both the incomplete penetrance and the male predominance in LHON are not fully explained yet.

There is no proper treatment to prevent the vision loss caused by LHON till now but medicines are available to promote ATP and decrease the oxidative stress.96,97 Recent study gives evidence that use of idebenone may be beneficial for LHON treatment and it has influential effect on visual acuity (VA) and visual evoked potential (VEP) in LHON patients.98 LHON is considered as a multifactorial disease with complex genetic and environmental interaction. Apart from the mitochondrial mutations, epigenetic factors play an important role in the disease pentrance and expression of the disease. On the basis of clinical studies, several environmental factors have been proposed to prompt LHON. Mitochondrial genetic variants associated with various diseases have been given in Table 2.

Table 2.

Mitochondrial genetic variants associated with various diseases.

Disease  Mitochondrial genetic variant
Leigh syndrome (LS)MT-ND1  m.4142 G > T 
MT-ND3  m.10158 T > Cm.10191 T > Cm.10197G > A 
MT-ND4  m.11777 C > Am.11778 G > A 
MT-ND5  m.13513G > Am.12706 T > Cm.13094 T > Cm.12706 T > C 
MT-ND6  m.14487T > Cm.14453 G > Am.14459 G > Am.14600G > A 
MT-ATP6  m.8993 T > Gm.8993 T > Cm.9176 T > Gm.9176 T > Cm.9185 T > Cm.9191 T > C 
MT-TK  m.8363A > G 
MT-TW  m.5537insT 
MT-CO3  m.9537insC 
MELASMT-ND1  m.3697G > Am.3946G > Am.3949 T > Cm.3308 T > Cm.3376G > Am.3481G > Am.3959G > Am.3995A > G 
MT-ND4  m.12015 T > Cm.11084A > Gm.11470A > C 
MT-ND5  m.12770A > Gm.13046 T > Cm.13063G > A 
MT-ND6  m.14453G > A 
MT-TL1  m.3243A > Gm.3271 T > C 
MT-CO3  m.9957 T > Cm.9997 T > C 
MT-CO1  m.6597C > A 
MT-CYB  m.14787del4 
Mitochondrial EncephalomyopathyMT-TL1  m.3242G > A 
MT-ND6  m.14487 T > C 
MT-ND3  m.10197G > A 
Myoclonic epilepsy with ragged-red fibers (MERRF)  MT-TK  m.8344A > Gm.8356 T > C 
Lethal Infantile Mitochondrial Disease  MT-TW  m.5567 T > C 
Leber's Hereditary Optic Neuropathy (LHON)MT-ND1  m.3460G > A 
MT-ND4  m.11778G > A 
MT-ND6  m.14484 T > C 

Some of the papers have suggested that alcohol and tobacco consumption are one of the main environmental factors which trigger vision loss in LHON.99–104 Tobacco smoke contains mixture of toxic contents including free radicals which make alterations in the ETC mechanism and it could make a synergic effect with alcohol in the LHON condition.99 Reports showed that persons who have mt.3460 and mt.14484 LHON mutations have high chances to get disease condition by high consumption of alcohol and tobacco102,105,106 reported that smoking is significantly associated with disease penetrance, degree of smoking and number of years smoked correlated with increased risk of developing symptoms. In contradictory to this reports, a study of affected and unaffected siblings from 80 sibships with LHON did not show any significant deleterious association between alcohol or tobacco consumption with vision loss in diseased condition.107

Other than the tobacco and alcohol consumption, some other environmental factors are also involved in the epigenetic mechanism of LHON. Antiretroviral drugs of the nucleoside analog (zidovudine) class are known to be associated with mitochondrial toxicity.108 Clinical studies are reported in some individual cases of LHON associated with antiretroviral therapy for human immunodeficiency virus (HIV) infection.109–111 HIV patients with family history of LHON who require antiretroviral therapy are more triggered for the severe vision loss.112 Je Hyun Seo et al. proposed antituberculosis medication might be an epigenetic factor of LHON in patients with primary mutation.113 In one of the case, report showed clinical expression of LHON precipitated by carbon monoxide poisoning who have mitochondrial primary mutation.114 Long exposure to n-hexane and other organic solvent uncouples mitochondrial respiration and impairs ATP synthesis, this suggest that these compounds could be a triggering epigenetic factor for LHON.115 Occupational exposure to polycyclic aromatic hydrocarbons (PAH) may provide pro-oxidative effect to the mitochondrial dysfunction for the person who has primary LHON mutation and it causes vision loss. Studies have been reported vision loss by LHON after the person had been exposed to rubber tire fire and suggesting that it could be a factor to trigger epigenetic mechanism in LHON.116,117 More validated data and research studies are required to confirm these factors and epigenetics as a cause for LHON. Understanding and identification of clinical and environmental factors and its mechanism of epigenetic changes would help to open a novel therapeutic method and more understanding of the disease condition.

Epigenetic modification of nuclear genes involved in mitochondrial diseases

According to proteomics survey, approximately 67% of mitochondrial proteins are present in the mitochondrial matrix, followed by 21% located within the inner mitochondrial membrane, 6% of proteins reside in the inner membrane space and 4% present in the outer mitochondrial membrane and 99% of these mitochondrial proteins are encoded by nuclear genome.118 Changes in mitochondrial protein expression leads to defective oxidative phosphorylation and ATP synthesis which leads to cell death and energy deficiency in cells. This metabolic changes could be the reason for many mitochondrial diseases and other complex disorders. nDNAs are protected with histones but not in mtDNA, that is the major difference between these two genomes. Post-translational histone modification and various DNA methylations regulate nuclear gene expression and protein synthesis in the cell. This kind of epigenetic change will also happen for nuclear encoded mitochondrial genes, which results in decreased level of mitochondrial proteins and leads to dysfunction of mitochondria. Adequate epigenetic studies help to perceive the relevance of each mitochondrial protein associated with the complex diseases. Researches in epigenetic regulation of nuclear encoded mitochondrial genes will lead to better understanding of various diseases and increases the chances for better therapeutics in future. But the epigenetic research is still not much explored in nuclear encoded mitochondrial proteins in disease conditions (Fig. 1).

Figure 1.

Illustration of how epigenetics involved in mitochondrial disease progression. Epigenetic factors modify histone proteins in chromatin and it affects gene regulation. Altered gene expression leads to depletion in protein level which results improper assembly of subunits in complex 1. This will affect the functioning of mitochondria and oxidative stress takes place. Mitochondrial damage leads to cell death and it causes various degenerative diseases.

(0.12MB).

Manganese Superoxide Dismutase (SOD2), encoded by nuclear gene sod2, is an important mitochondrial antioxidant enzyme whose activity has broad implications in health and disease. Many studies have been done in epigenetic regulation of this gene in cancer biology with free radical theory. Studies have reported that reduced SOD activity with CpG methylation in the intronic enhancer region119 and with reduced H3K4me2 histone modification at intronic enhancer which leading to the altered expression of MnSOD.120 In diabetic condition , sod2 is modified with methyl H4K20 and H3K9 acetylation in the promoter region.121 H3K4 histone methylation of retinal sod2 gene has crucial role in development of diabetic retinopathy.122 These studies raise the possibility to use therapeutic targeted towards regulation of methylation status of histones to prevent inhibition of MnSOD and protect mitochondrial damage. In paraganglioma disease condition, succinate dehydrogenase(SDH) gene expression downregulated with H3K27me3 histone modification in the nuclear gene and it can be reversed by overexpression of the JMJD3 histone demethylase.123 Abnormal hypermethylation in the promoter region of the VDAC (Voltage Dependent Anion Channels) gene shows reduced expression of VDAC porin protein and it causes low sperm motility in athenospermia condition in men.124 Neurodegenerative diseases are more with multifactorial etiology having a very high ability to make changes in quality and standards of life.125–128 Along with mitochondrial dysfunctions and epigenetics changes, evidences are indicating that various metabolic pathways have been involved in progression and development of neurodegenerative condition.129–132

Epigenetic regulation of nuclear encoded mitochondrial gene has an important role in the disease progression and cell functioning. Studies have been focused on various aspects of epigenetics play a distinguished role in various ocular neurodegenerative diseases.133 Downregulation of mitochondrial proteins leads to abnormal metabolic condition in cell through damaged oxidative phosphorylation and free radical formation. Cell-based approaches on ocular diseases are a new dimension towards treatment approaches treatment.134 This condition will cause cell death and leads to severe diseases. But still more research is needed to clarify the actual mechanisms. So understanding of epigenetic mechanism and designing therapeutic for the epigenetic targets will improve the treatment efficiency in various diseases.

Conclusion

The purpose of this review was to find out the possible ways of how epigenetics can affect the process of mitochondrial oxidative phosphorylation leading to various diseases focusing on ocular diseases. There is a solid incentive to know more about epigenetics and reconnoiter the role of epigenetics in terms of mitochondrial diseases because these are the factors that has the potential to understand variable penetrance, phenotypic heterogeneity and environmental factors that induce disorders from this group. The current technology has the ability to directly evaluate epigenetic discrepancy in the nuclear genome or mitochondria. These situations have ultimately led to the urge of being able to find a permanent solution. Therefore, our focus is to develop on the idea of epigenetic modifications involved in mitochondrial diseases leading to various optical neuropathies, especially LHON.

Funding

The authors would like to thank the Science and Engineering Research Board (SERB) for providing Early Career Research Award (ECR/2018/000718), India to complete this article successfully.

References
[1.]
S. Bannwarth, V. Procaccio, A.S. Lebre, et al.
Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders.
J Med Genet, 50 (2013), pp. 704-714
[2.]
R.J. Rodenburg.
Mitochondrial complex I-linked disease.
Biochim Biophys Acta - Bioenerg., 1857 (2016), pp. 938-945
[3.]
G. Cenini, A. Lloret, R. Cascella.
Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view.
Oxid Med Cell Longev, 2019 (2019), pp. 2105607
[4.]
A. Moosavi, A. Motevalizadeh Ardekani.
Role of epigenetics in biology and human diseases.
Iran Biomed J., 20 (2016), pp. 246-258
[5.]
Y. Hatefi.
The mitochondrial electron transport and oxidative phosphorylation system.
Annu Rev Biochem, 54 (1985), pp. 1015-1069
[6.]
J.-W. Taanman.
The mitochondrial genome: structure, transcription, translation and replication.
Biochim Biophys Acta - Bioenerg., 1410 (1999), pp. 103-123
[7.]
H.M. McBride, M. Neuspiel, S. Wasiak.
Mitochondria: more than just a powerhouse.
Curr Biol, 16 (2006), pp. R551-R560
[8.]
W.J.H. Koopman, F. Distelmaier, J.A.M. Smeitink, P.H.G.M. Willems.
OXPHOS mutations and neurodegeneration.
[9.]
M.G. Hanna, I.P. Nelson.
Genetics and molecular pathogenesis of mitochondrial respiratory chain diseases.
Cell Mol Life Sci C, 55 (1999), pp. 691-706
[10.]
G. Tuschen, U. Sackmann, U. Nehls, H. Haiker, G. Buse, H. Weiss.
Assembly of NADH: Ubiquinone reductase (complex I) in Neurospora mitochondria: independent pathways of nuclear-encoded and mitochondrially encoded subunits.
J Mol Biol, 213 (1990), pp. 845-857
[11.]
U. Brandt.
Energy converting NADH: quinone oxidoreductase (Complex I).
[12.]
R.J.R.J. Janssen, L.G. Nijtmans, L.P. van den Heuvel, J.A.M. Smeitink.
Mitochondrial complex I: structure, function and pathology.
J Inherit Metab Dis, 29 (2006), pp. 499-515
[13.]
V. Zickermann, S. Kerscher, K. Zwicker, M.A. Tocilescu, M. Radermacher, U. Brandt.
Architecture of complex I and its implications for electron transfer and proton pumping.
Biochim Biophys Acta, 1787 (2009), pp. 574-583
[14.]
J.L. Burman, L.S. Itsara, E.-B. Kayser, et al.
A Drosophila model of mitochondrial disease caused by a complex I mutation that uncouples proton pumping from electron transfer.
Dis Model Mech, 7 (2014), pp. 1165-1174
[15.]
D.A. Stroud, E.E. Surgenor, L.E. Formosa, et al.
Accessory subunits are integral for assembly and function of human mitochondrial complex I.
Nature., 538 (2016), pp. 123-126
[16.]
R.N. Lightowlers, R.W. Taylor, D.M. Turnbull.
Mutations causing mitochondrial disease: what is new and what challenges remain?.
Science (80-), 349 (2015), pp. 1494 LP-1499
[17.]
B. Andrews, J. Carroll, S. Ding, I.M. Fearnley, J.E. Walker.
Assembly factors for the membrane arm of human complex I.
Proc Natl Acad Sci., 110 (2013), pp. 18934 LP-18939
[18.]
S. Guerrero-Castillo, F. Baertling, D. Kownatzki, et al.
The assembly pathway of mitochondrial respiratory chain complex I.
Cell Metab, 25 (2017), pp. 128-139
[19.]
M.R.M. Mckenzie.
Assembly factors of human mitochondrial complex I and their defects in disease.
IUBMB Life, 62 (2010), pp. 497-502
[20.]
D. De Rasmo, G. Palmisano, S. Scacco, et al.
Phosphorylation pattern of the NDUFS4 subunit of complex I of the mammalian respiratory chain.
Mitochondrion., 10 (2010), pp. 464-471
[21.]
H. Heide, L. Bleier, M. Steger, et al.
Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex.
Cell Metab, 16 (2012), pp. 538-549
[22.]
H. Sies.
Oxidative stress: From basic research to clinical application.
Am J Med., 91 (1991), pp. S31-S38
[23.]
A. Stepanova, C. Konrad, S. Guerrero-Castillo, et al.
Deactivation of mitochondrial complex I after hypoxia-ischemia in the immature brain.
J Cereb Blood Flow Metab, 39 (2019), pp. 1790-1802
[24.]
F.M. Yakes, B. Van Houten.
Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress.
Proc Natl Acad Sci U S A, 94 (1997), pp. 514-519
[25.]
D.A. Clayton.
Transcription of the mammalian mitochondrial genome.
Annu Rev Biochem, 53 (1984), pp. 573-594
[26.]
P. Pérez-Treviño, M. Velásquez, N. García.
Mechanisms of mitochondrial DNA escape and its relationship with different metabolic diseases.
Biochim Biophys Acta - Mol Basis Dis, 2020 (1866), pp. 165761
[27.]
A. Picca, F. Guerra, R. Calvani, et al.
Generation and release of mitochondrial-derived vesicles in health, aging and disease.
J Clin Med, 9 (2020), pp. 1440
[28.]
M. Ihara, H. Tanaka, M. Yashiro, Y. Nishimura.
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with chronic renal failure: report of mother-child cases.
Rinsho Shinkeigaku, 36 (1996), pp. 1069-1073
[29.]
Y.H. Wei, C.Y. Lu, C.Y. Wei, Y.S.L.H. Ma.
Oxidative stress in human aging and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system.
Chin J Physiol, 44 (2001), pp. 1-11
[30.]
K. Oexle, A. Zwirner.
Advanced telomere shortening in respiratory chain disorders.
Hum Mol Genet, 6 (1997), pp. 905-908
[31.]
C.S. Lin, M.S. Sharpley, W. Fan, et al.
Mouse mtDNA mutant model of Leber hereditary optic neuropathy.
Proc Natl Acad Sci U S A, 109 (2012), pp. 20065-20070
[32.]
Y. Guo, C.-I. Li, Q. Sheng, et al.
Very low-level heteroplasmy mtDNA variations are inherited in humans.
J Genet Genomics, 40 (2013), pp. 607-615
[33.]
V. Carelli, M. Rugolo, G. Sgarbi, et al.
Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration.
Biochim Biophys Acta - Bioenerg., 1658 (2004), pp. 172-179
[34.]
M.Y. Yen, S.H. Kao, A.G.W.Y. Wang.
Increased 8-hydroxy-2′-deoxyguanosine in leukocyte DNA in Leber's hereditary optic neuropathy.
Invest Ophthalmol Vis Sci, 45 (2004), pp. 1688-1691
[35.]
A. Ghelli, A.M. Porcelli, C. Zanna, A. Martinuzzi, V. Carelli, M. Rugolo.
Protection against oxidant-induced apoptosis by exogenous glutathione in Leber hereditary optic neuropathy cybrids.
Invest Ophthalmol Vis Sci, 49 (2008), pp. 671-676
[36.]
Y. Zhuo, H. Luo, K. Zhang.
Leber hereditary optic neuropathy and oxidative stress.
Proc Natl Acad Sci., 109 (2012), pp. 19882-19883
[37.]
H. Antonicka, S.C. Leary, G.-H. Guercin, et al.
Mutations in COX10 result in a defect in mitochondrial heme A biosynthesis and account for multiple, early-onset clinical phenotypes associated with isolated COX deficiency.
Hum Mol Genet, 12 (2003), pp. 2693-2702
[38.]
S.E. Calvo, V.K. Mootha.
The mitochondrial proteome and human disease.
Annu Rev Genomics Hum Genet, 11 (2010), pp. 25-44
[39.]
E. Malfatti, M. Bugiani, F. Invernizzi, et al.
Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathy.
Brain., 130 (2007), pp. 1894-1904
[40.]
Y. Koga, M. Ishibashi, I. Ueki, et al.
Effects of="sc">l-arginine on the acute phase of strokes in three patients with MELAS.
Neurology., 58 (2002), pp. 827-828
[41.]
S. Frey, G. Geffroy, V. Desquiret-Dumas, et al.
The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model.
Biochim Biophys Acta - Mol Basis Dis., 1863 (2017), pp. 284-291
[42.]
H. Pagniez-Mammeri, M. Rak, A. Legrand, P. Bénit, P. Rustin, A. Slama.
Mitochondrial complex I deficiency of nuclear origin: II. Non-structural genes.
Mol Genet Metab, 105 (2012), pp. 173-179
[43.]
R.H. Triepels, L.P. Van den Heuvel, J.M.S.J. Trijbels.
Respiratory chain complex I deficiency.
Am J Med Genet, 106 (2001), pp. 37-45
[44.]
J. Loeffen, J. Smeitink, R. Triepels, et al.
The first nuclear-encoded complex I mutation in a patient with Leigh Syndrome.
Am J Hum Genet, 63 (1998), pp. 1598-1608
[45.]
S. Rahman, R.B. Blok, H.H. Dahl, D.M. Danks, D.M. Kirby, C.W. Chow, J.T.D. Christodoulou.
Leigh syndrome: clinical features and biochemical and DNA abnormalities.
Ann Neurol, 39 (1996), pp. 343-351
[46.]
D. Piekutowska-Abramczuk, Z. Assouline, L. Mataković, et al.
NDUFB8 mutations cause mitochondrial complex I deficiency in individuals with Leigh-like encephalomyopathy.
Am J Hum Genet, 102 (2018), pp. 460-467
[47.]
P. Bénit, D. Chretien, N. Kadhom, et al.
Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency.
Am J Hum Genet, 68 (2001), pp. 1344-1352
[48.]
M.A. Martín, A. Blázquez, L.G. Gutierrez-Solana, et al.
Leigh syndrome associated with mitochondrial complex I deficiency due to a novel mutation in the NDUFS1 gene.
Arch Neurol, 62 (2005), pp. 659-661
[49.]
L.-H. Ngu, L. Nijtmans, F. Distelmaier, et al.
A catalytic defect in mitochondrial respiratory chain complex I due to a mutation in NDUFS2 in a patient with Leigh syndrome.
Biochim Biophys Acta, 2012 (1822), pp. 168-175
[50.]
H.A.L. Tuppen, V.E. Hogan, L. He, et al.
The p.M292T NDUFS2 mutation causes complex I-deficient Leigh syndrome in multiple families.
Brain., 133 (2010), pp. 2952-2963
[51.]
P. Bénit, A. Slama, F. Cartault, et al.
Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome.
J Med Genet, 41 (2004), pp. 14-17
[52.]
P. Bénit, J. Steffann, S. Lebon, et al.
Genotyping microsatellite DNA markers at putative disease loci in inbred/multiplex families with respiratory chain complex I deficiency allows rapid identification of a novel nonsense mutation (IVS1nt −1) in the NDUFS4 gene in Leigh syndrome.
Hum Genet, 112 (2003), pp. 563-566
[53.]
L. van den Heuvel, W. Ruitenbeek, R. Smeets, et al.
Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit.
Am J Hum Genet, 62 (1998), pp. 262-268
[54.]
S.M.S. Budde, L.P.W.J. van den Heuvel, A.J. Janssen, et al.
Combined enzymatic complex I and III deficiency associated with mutations in the nuclear encoded NDUFS4 gene.
Biochem Biophys Res Commun, 275 (2000), pp. 63-68
[55.]
V. Petruzzella, R. Vergari, I. Puzziferri, et al.
A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome.
Hum Mol Genet, 10 (2001), pp. 529-536
[56.]
S.L. Anderson, W.K. Chung, J. Frezzo, et al.
A novel mutation in NDUFS4 causes Leigh syndrome in an Ashkenazi Jewish family.
J Inherit Metab Dis, 31 (2008), pp. 461-467
[57.]
R.H. Triepels, L.P. Van Den Heuvel, J.L.C.M. Loeffen, et al.
Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I.
[58.]
S. Lebon, L. Minai, D. Chretien, et al.
A novel mutation of the NDUFS7 gene leads to activation of a cryptic exon and impaired assembly of mitochondrial complex I in a patient with Leigh syndrome.
Mol Genet Metab, 92 (2007), pp. 104-108
[59.]
V. Procaccio, D.C. Wallace.
Late-onset Leigh syndrome in a patient with mitochondrial complex I NDUFS8 mutations.
Neurology., 62 (2004), pp. 1899-1901
[60.]
S.J.G. Hoefs, C.E.J. Dieteren, F. Distelmaier, et al.
NDUFA2 complex I mutation leads to Leigh disease.
Am J Hum Genet, 82 (2008), pp. 1306-1315
[61.]
S.J.G. Hoefs, F.J. van Spronsen, E.W.H. Lenssen, et al.
NDUFA10 mutations cause complex I deficiency in a patient with Leigh disease.
Eur J Hum Genet, 19 (2011), pp. 270-274
[62.]
S.J.G. Hoefs, C.E.J. Dieteren, R.J. Rodenburg, et al.
Baculovirus complementation restores a novel NDUFAF2 mutation causing complex I deficiency.
Hum Mutat, 30 (2009), pp. E728-E736
[63.]
S.J.G. Hoefs, C.E.J. Dieteren, R.J. Rodenburg, et al.
High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency.
Nat Genet, 42 (2010), pp. 851-858
[64.]
M. Schuelke, J. Smeitink, E. Mariman, J. Loeffen, B. Plecko, F. Trijbels, S. Stöckler-Ipsiroglu, L. Van den Heuvel.
Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy.
Nat Genet, 21 (1999), pp. 260-261
[65.]
M. Bugiani, F. Invernizzi, S. Alberio, et al.
Clinical and molecular findings in children with complex I deficiency.
Biochim Biophys Acta - Bioenerg, 1659 (2004), pp. 136-147
[66.]
P. Potluri, A. Davila, E. Ruiz-Pesini, et al.
A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease.
Mol Genet Metab, 96 (2009), pp. 189-195
[67.]
J.A. Mayr, O. Bodamer, T.B. Haack, et al.
Heterozygous mutation in the X chromosomal NDUFA1 gene in a girl with complex I deficiency.
Mol Genet Metab, 103 (2011), pp. 358-361
[68.]
S.E. Calvo, E.J. Tucker, A.G. Compton, et al.
High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency.
Nat Genet, 42 (2010), pp. 851-858
[69.]
T.B. Haack, K. Danhauser, B. Haberberger, et al.
Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency.
Nat Genet, 42 (2010), pp. 1131-1134
[70.]
P. Bénit, R. Beugnot, D. Chretien, et al.
Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy.
Hum Mutat, 21 (2003), pp. 582-586
[71.]
I. Ogilvie, N.G. Kennaway, E.A. Shoubridge.
A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy.
J Clin Invest, 115 (2005), pp. 2784-2792
[72.]
I. Berger, E. Hershkovitz, A. Shaag, S. Edvardson, A. Saada, O. Elpeleg.
Mitochondrial complex I deficiency caused by a deleterious NDUFA11 mutation.
Ann Neurol, 63 (2008), pp. 405-408
[73.]
M. Filosto, M. Scarpelli, M.S. Cotelli, et al.
The role of mitochondria in neurodegenerative diseases.
J Neurol, 258 (2011), pp. 1763-1774
[74.]
Y. Wu, M. Chen, J. Jiang.
Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling.
Mitochondrion., 49 (2019), pp. 35-45
[75.]
A.K. Pollard, E.L. Craig, L. Chakrabarti.
Mitochondrial complex 1 activity measured by spectrophotometry is reduced across all brain regions in ageing and more specifically in neurodegeneration.
PLoS One, 11 (2016), pp. e0157405
[76.]
G. Lenaz, C. Bovina, M. D'Aurelio, et al.
Role of mitochondria in oxidative stress and aging.
Ann N Y Acad Sci, 959 (2002), pp. 199-213
[77.]
A.H.V. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, C. Marsden.
Mitochondrial complex I deficiency in Parkinson's disease.
[78.]
A.H. Schapira.
Neurobiology and treatment of Parkinson's disease.
Trends Pharmacol Sci, 30 (2009), pp. 41-47
[79.]
L. Tretter, I. Sipos, V. Adam-Vizi.
Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.
Neurochem Res, 29 (2004), pp. 569-577
[80.]
G.U. Höglinger, G. Carrard, P.P. Michel, et al.
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
J Neurochem, 86 (2003), pp. 1297-1307
[81.]
G.U. Höglinger, A. Lannuzel, M.E. Khondiker, et al.
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy.
J Neurochem, 95 (2005), pp. 930-939
[82.]
M. Golpich, E. Amini, Z. Mohamed, R. Azman Ali, N. Mohamed Ibrahim, A. Ahmadiani.
Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment.
CNS Neurosci Ther, 23 (2017), pp. 5-22
[83.]
M. Hashimoto, E. Rockenstein, L.M.E. Crews.
Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Neuromolecular Med, 4 (2003), pp. 21-36
[84.]
M. Manczak, B.S. Park, Y. Jung, P.H. Reddy.
Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease.
Neuromolecular Med, 5 (2004), pp. 147-162
[85.]
K. Chandrasekaran, K. Hatanpää, D.R. Brady, S.I. Rapoport.
Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease.
Exp Neurol, 142 (1996), pp. 80-88
[86.]
R. Fukuyama, K. Hatanpää, S.I. Rapoport, K. Chandrasekaran.
Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients.
Brain Res, 713 (1996), pp. 290-293
[87.]
S. Melov, P.A. Adlard, K. Morten, et al.
Mitochondrial oxidative stress causes hyperphosphorylation of tau.
[88.]
A.C. Andreazza, L. Shao, J.-F. Wang, L.T. Young.
Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder.
Arch Gen Psychiatry, 67 (2010), pp. 360-368
[89.]
S.A. Schrier, M.J. Falk.
Mitochondrial disorders and the eye.
Curr Opin Ophthalmol, 22 (2011), pp. 325-331
[90.]
S.A. Madsen-Bouterse, G. Mohammad, M. Kanwar, R.A. Kowluru.
Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression.
Antioxid Redox Signal, 13 (2010), pp. 797-805
[91.]
J. Guy, W.J. Feuer, J.L. Davis, et al.
Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results.
Ophthalmology., 124 (2017), pp. 1621-1634
[92.]
K. Dimitriadis, M. Leonhardt, P. Yu-Wai-Man, et al.
Leber's hereditary optic neuropathy with late disease onset: clinical and molecular characteristics of 20 patients.
Orphanet J Rare Dis, 9 (2014), pp. 158
[93.]
P. Yu-Wai-Man, M. Votruba, A.T. Moore, P.F. Chinnery.
Treatment strategies for inherited optic neuropathies: past, present and future.
Eye (Lond), 28 (2014), pp. 521-537
[94.]
M. Chang.
Leber's hereditary optic neuropathy misdiagnosed as optic neuritis and Lyme disease in a patient with multiple sclerosis.
[95.]
C. Lee, K.-A. Park, G.-I. Lee, S.Y. Oh, J.-H. Min, B.J. Kim.
Leber's hereditary optic neuropathy following unilateral painful optic neuritis: a case report.
BMC Ophthalmol, 20 (2020), pp. 195
[96.]
T. Klopstock, P. Yu-Wai-Man, K. Dimitriadis, et al.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Brain., 134 (2011), pp. 2677-2686
[97.]
W.D. Shrader, A. Amagata, A. Barnes, et al.
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
Bioorg Med Chem Lett, 21 (2011), pp. 3693-3698
[98.]
X. Zhao, Y. Zhang, L. Lu, H. Yang.
Therapeutic effects of idebenone on Leber hereditary optic neuropathy.
Curr Eye Res, 45 (2020), pp. 1315-1323
[99.]
M.E. Cullom, K.L. Heher, N.R. Miller, P.J. Savino, D.R. Johns.
Leber's hereditary optic neuropathy masquerading as tobacco-alcohol amblyopia.
Arch Ophthalmol, 111 (1993), pp. 1482-1485
[100.]
K.C. Golnik, E.R. Schaible.
Folate-responsive optic neuropathy.
J Neuroophthalmol, 14 (1994), pp. 163-169
[101.]
P. Riordan-Eva, M.D. Sanders, G.G. Govan, M.G. Sweeney, J. Da Costa, A.E. Harding.
The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation.
Brain., 118 (1995), pp. 319-337
[102.]
R.M. Chalmers, A.E. Harding.
A case-control study of Leber's hereditary optic neuropathy.
Brain., 119 (1996), pp. 1481-1486
[103.]
A.A. Sadun, V. Carelli, S.R. Salomao, A. Berezovsky, P.A. Quiros, F. Sadun, A.M. DeNegri, R. Andrade, M. Moraes, A. Passos, P. Kjaer, J. Pereira, M.L. Valentino, S.B.R. Schein.
Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy.
Am J Ophthalmol, 136 (2003), pp. 231-238
[104.]
M.A. Kirkman, A. Korsten, M. Leonhardt, K. Dimitriadis, I.F. De Coo, T. Klopstock, P.G. Griffiths, G. Hudson, P.F. Chinnery, PY-W-M.
Quality of life in patients with Leber hereditary optic neuropathy.
Invest Ophthalmol Vis Sci, 50 (2009), pp. 3112-3115
[105.]
D.R. Johns, K.H. Smith, N.R. Miller, M.E. Sulewski, W.B. Bias.
Identical twins who are discordant for Leber's hereditary optic neuropathy.
Arch Ophthalmol, 111 (1993), pp. 1491-1494
[106.]
K. Tsao, P.A. Aitken, D. Johns.
Smoking as an aetiological factor in a pedigree with Leber's hereditary optic neuropathy.
Br J Ophthalmol, 83 (1999), pp. 577-581
[107.]
J.B. Kerrison, N.R. Miller, F. Hsu, et al.
A case-control study of tobacco and alcohol consumption in Leber hereditary optic neuropathy.
Am J Ophthalmol, 130 (2000), pp. 803-812
[108.]
K. Brinkman, H.J.M. ter Hofstede, D.M. Burger, J.A.M. Smeitink, P.P. Koopmans.
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.
[109.]
C. Lüke, O.A. Cornely, J. Fricke, E. Lehrer, K.U. Bartz-Schmidt.
Late onset of Leber's hereditary optic neuropathy in HIV infection.
Br J Ophthalmol, 83 (1999), pp. 1204-1205
[110.]
S. Shaikh, C. Ta, A.A.M.S. Basham.
Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection.
Am J Ophthalmol, 131 (2001), pp. 143-145
[111.]
Warner JEA, K.M. Ries.
Optic Neuropathy in a Patient With AIDS.
[112.]
D.A. Mackey, J.H. Fingert, J.Z. Luzhansky, et al.
Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus.
Eye., 17 (2003), pp. 312-317
[113.]
J.H. Seo, J.-M. Hwang, S.S. Park.
Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy.
Clin Experiment Ophthalmol, 38 (2010), pp. 363-366
[114.]
J.M. Hwang, H.W. Park.
Carbon monoxide poisoning as an epigenetic factor for Leber's hereditary optic neuropathy.
Korean J Ophthalmol, 10 (1996), pp. 122-123
[115.]
V. Carelli, F. Franceschini, S. Venturi, et al.
Grand rounds: could occupational exposure to n-hexane and other solvents precipitate visual failure in leber hereditary optic neuropathy?.
Environ Health Perspect, 115 (2007), pp. 113-115
[116.]
A. Rufa, M.T. Dotti, E. Cardaioli, P. Da Pozzo, A. Federico.
Leber hereditary optic neuropathy in 2 of 4 siblings with 11778 mtDNA mutation: clinical variability or effect of toxic environmental exposure?.
Eur Neurol, 53 (2005), pp. 32-34
[117.]
R.N. Sanchez, A.J. Smith, V. Carelli, A.A. Sadun, J.L. Keltner.
Leber hereditary optic neuropathy possibly triggered by exposure to tire fire.
[118.]
D.J. Pagliarini, S.E. Calvo, B. Chang, et al.
A mitochondrial protein compendium elucidates complex I disease biology.
Cell., 134 (2008), pp. 112-123
[119.]
Y. Huang, J. Peng, L.W. Oberley, F.E. Domann.
Transcriptional inhibition of manganese superoxide dismutase (SOD2) gene expression by DNA methylation of the 5′ CpG Island.
Free Radic Biol Med, 23 (1997), pp. 314-320
[120.]
M.J. Hitchler, L.W. Oberley, F.E. Domann.
Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Free Radic Biol Med, 45 (2008), pp. 1573-1580
[121.]
Q. Zhong, R.A. Kowluru.
Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy.
Diabetes., 60 (2011), pp. 1304-1313
[122.]
Q. Zhong, R.A. Kowluru.
Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation.
Invest Ophthalmol Vis Sci, 54 (2013), pp. 244-250
[123.]
A.M. Cervera, J.-P. Bayley, P. Devilee, K.J. McCreath.
Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells.
Mol Cancer, 8 (2009), pp. 89
[124.]
A. Xu, Y. Hua, J. Zhang, et al.
Abnormal hypermethylation of the VDAC2 promoter is a potential cause of idiopathic asthenospermia in men.
Sci Rep, 6 (2016), pp. 37836
[125.]
A. Venugopal, M. Iyer, V. Balasubramanian, B. Vellingiri.
Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease.
Acta Neuropsychiatr, 32 (2020), pp. 65-71
[126.]
S. Mohana Devi, I. Mahalaxmi, N.P. Aswathy, V. Dhivya, V. Balachandar.
Does retina play a role in Parkinson's disease?.
Acta Neurol Belg, 120 (2020), pp. 257-265
[127.]
D. Venkatesan, M. Iyer, S RW, G L, B. Vellingiri.
The association between multiple risk factors, clinical correlations and molecular insights in Parkinson's disease patients from Tamil Nadu population, India.
Neurosci Lett, 755 (2021), pp. 135903
[128.]
M. Gomathi, S. Padmapriya, V. Balachandar.
Drug studies on Rett syndrome: from bench to bedside.
J Autism Dev Disord, 50 (2020), pp. 2740-2764
[129.]
H. Ganesan, V. Balasubramanian, M. Iyer, et al.
mTOR signalling pathway - A root cause for idiopathic autism?.
[130.]
D. Venkatesan, M. Iyer, A. Narayanasamy, K. Siva, B. Vellingiri.
Kynurenine pathway in Parkinson's disease-An update.
eNeurologicalSci., 21 (2020), pp. 100270
[131.]
V. Balachandar, K. Rajagopalan, K. Jayaramayya, M. Jeevanandam, M. Iyer.
Mitochondrial dysfunction: a hidden trigger of autism?.
[132.]
B. Geetha, C. Sukumar, E. Dhivyadeepa, J.K. Reddy, V. Balachandar.
Autism in India: a case–control study to understand the association between socio-economic and environmental risk factors.
Acta Neurol Belg, 119 (2019), pp. 393-401
[133.]
S. Mohana Devi, I. Mahalaxmi, J. Kaavya, V. Chinnkulandhai, V. Balachandar.
Does epigenetics have a role in age related macular degeneration and diabetic retinopathy?.
Genes Dis, 8 (2021), pp. 279-286
[134.]
S. Mohana Devi, I. Mahalaxmi, P. Aswathy, V. Nair Dhivya, E. Nimmisha, K. Soumya, C. Manoj Kumar, R. Ayan, V.G. Abilash, V. Balachandar.
Oxidative stress and mitochondrial transfer: a new dimension towards Ocular diseases.
Copyright © 2021. Sociedad Española de Neurología
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos